PairX Bio’s Post

⏰ Just ONE DAY until our highly-anticipated webinar on bivalent degraders! Mark your calendars and join Katie and Thomas to explore the latest trends, emerging targets, and potential applications in cancer and non-cancer indications.👇 https://lnkd.in/e_gzbUpg Here's what you can expect: 🔬 Analysing novel bivalent degrader effectors (Top 5 Cancer and Non-Cancer) 📈 Addressing the commercial growth within the bivalent landscape 💊 Deep dive into the Preclinical and Clinical data success stories 🔍 Live Q&A, have your questions answered! #TPD #BivalentDegraders #PROTACS

A good picture conveys much more than words can express. This picture I stumbled upon perfectly captures the essence and spirit of Mirxes, and we decided to use it in place of another typical team picture featuring our CEO, CFO and HR VP 😅

Come and join me and Katie next week at our totally free webinar taking a deep dive into the bivalent degrader landscape.

Why have traditional drug discovery models failed to improve #PaediatricCancer care, and what we can do about it? Sam Daems from Waterland Private Equity & Cancer Grand Challenges PROTECT team took us through the challenges and why we need new #DrugDiscovery models like C-Further, Cancer Research Horizons & LifeArc's new international consortium for #ChildhoodCancer: https://lnkd.in/e5xJYm69

On the second day of CTA-Mas, let us introduce you to Jonathan Kwok 🎄 Jonathan is the cofounder of Infinitopes, a CTA alum company and a powehouse pioneer in precision immunomics medicines. Most recently, Infinitopes showcased their innovative breakthroughs on cancer vaccine development at SITC 2024, and shared their insight into a double-blind, Phase I/IIa clinical trial. Read the article here to learn more about their amazing trajectory and most recent advances in research: https://lnkd.in/e_rhZHs3 #precisionmedicine #cancervaccines #research #founderstory #oxford #CRUK #cancertech

Join our CEO, William Ho, as he shares the heartfelt inspiration behind IN8bio's focus on gamma-delta T cells. Our Chief Scientific Officer, Lawrence Lamb, PhD, was deeply moved by his experience with six young #leukemia patients in the 1990s, leading him to a lifelong mission. Discover how gamma-delta T cells, with the unique ability to distinguish between healthy and cancerous tissue, are at the core of our groundbreaking cancer therapies. Please watch for more about the story and learn about our innovative DeltEx platform. Together, we're pushing the boundaries of science to achieve #CancerZero. #IN8bio #GDTcells #GammaDeltaTCells #Biotech #CancerResearch

Last week I attended this Innovation Series Seminar! I am really happy for what NUNO Prego Ramos has achieved! Also, this success story is an inspiration for biotech projects from Portugal! The quality of the content was huge, but I will highlight: 1) Aim for something bigger than ourselves; 2) Negative experiences give you lessons to learn; 3) Manage people with transparency. I would say that the key to success is take care of your relationships! #entrepreneurship #innovation #technologytransfer

In case you missed it: Last week, the Immatics team was onsite in Houston, Texas, for the 39th Annual Society for Immunotherapy of Cancer (SITC) conference, where two oral presentations and multiple posters on our clinical and preclinical-stage candidates were presented. The conference was also a great opportunity for our Tübingen and Munich colleagues to connect with the Houston team. Thank you, SITC, for another outstanding and informative conference! Interested in the data? Read the full press release here: https://lnkd.in/dHUurcEv #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews #SITC

With the Childhood Cancer Data Initiative’s Molecular Targets Platform, researchers can analyze molecular data to uncover new therapeutic targets and develop innovative treatment approaches. Learn more. https://go.nih.gov/JybD43r #Data4ChildhoodCancer

#MobileClin2024 is kicking off with a patient-led discussion on the diverse range of preferences and needs when utilizing mobile technologies in clinical trials. Thank you to our moderator, Lani Hashimoto, Novartis, and patient advocates Mackenzie Abramson, Global Genes, Patrick Gee Sr., iAdvocate, Inc., Celline Mitchell, and Rucha Shah, ECOG-ACRIN Cancer Research Group for sharing your perspectives. Learn more about the 11th annual program here: https://lnkd.in/ggv8w76s #MobileClin2024 #clinicaltrials #patientvoice #patientadvocacy"